Sign in
CompletedPhase 2

INDV-6001 Multiple-Dose Pharmacokinetic Study

Key facts

Who runs it
Indivior Inc.
Where
Bountiful, Chicago, Dayton, DeSoto, Flowood, Houston, Marlton, Miami Lakes, Richardson, San Diego, and Staten Island, United StatesSee the 11 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
123 people enrolled
Started
17 Sept 2024
Ended
21 Jan 2026
Type of study
Interventional, 9 groups
Treatments tested
  • INDV-6001
  • Suboxone
  • Sublocade
Record updated
16 March 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Participants are eligible to be included in any cohort open to enrolment in the study only if all of the following criteria apply:
  • Has signed the ICF and have the ability to understand and comply with the requirements and restrictions listed therein
  • Is an adult (male or female) between the ages of 18 and 65 years, inclusive, at the time of signing the ICF
  • Has a BMI of ≥18.0 to ≤33.0 kg/m2
  • Is seeking MOUD and currently meets or has documented history of moderate or severe OUD as per DSM-5 criteria. For Cohorts 1-4 only: can be dose-adjusted to 12 to 16 mg SUBOXONE QD or currently taking TM BUP for OUD and can be dose-adjusted to 12 to 16 mg SUBOXONE QD
  • Agrees not to take any BUP-containing products, other than those administered for the current study, throughout the duration of the study
  • If a woman of childbearing potential, not pregnant or lactating and agrees to follow contraception guidelines per protocol; if a women of non-childbearing potential (WONCBP), is:; Postmenopausal (defined as no menses for 12 months without an alternative medical cause and confirmed by high FSH level of >30 mIU/mL in women not using hormonal contraception or hormonal replacement therapy) or; Permanently sterilised (eg, bilateral tubal occlusion, bilateral tubal ligation, complete hysterectomy, bilateral salpingectomy, bilateral oophorectomy)
  • If a man, agrees to follow contraception guidelines per protocol 5.2 Exclusion Criteria; A participant will not be eligible for inclusion in this study if any of the following criteria apply:
  • Has current diagnosis or medical condition, other than OUD, requiring chronic opioid treatment
  • Has a concurrent primary substance use disorder, as defined by DSM-5 criteria, other than opioid, tobacco, cannabis, or mild to moderate alcohol use disorders
  • Has an injection area unsuitable for SC injections (eg, nodules, scarring, lesions, excessive pigment) in the areas designated for possible injection in the study
  • Is currently using another MOUD treatment other than TM BUP (eg, SUBOXONE) or has had prior treatment with any long-acting injectable form of a BUP-containing product in the past 18 months (or if 18-24 months with a positive UDS) prior to consent; treatment with oral naltrexone or methadone products within 14 days prior to consent (or positive UDS for methadone at Screening); or treatment with depot naltrexone within the 3 months prior to consent
  • Has had significant traumatic injury or major surgical procedure (as defined by the investigator) within 30 days prior to the first dose of INDV-6001 or still recovering from such prior injury or surgery
  • Has congenital long QT syndrome, history of prolonged QT in the 3 months prior to screening, or a corrected QT interval (Fridericia's - QTcF) >450 msec (male) or >470 msec (female), or history of risk factors for Torsades de Pointes. Has known personal history of taking Class IA antiarrhythmic medications (eg, quinidine, procainamide, disopyramide) or Class III antiarrhythmic medications (eg, sotalol, amiodarone) or other mediations that prolong the QT interval
  • Has known family history of congenital QT prolongation or sudden unexplained death
  • Is currently taking (within the 30 days prior to signing the ICF) prescription or OTC medications that are clinically relevant moderate or strong cytochrome P450 (CYP) 3A4 or CYP 2C8 inducers or inhibitors (eg, rifampin, azole antifungals [eg, ketoconazole], macrolide antibiotics [eg, erythromycin])
  • Has a history of suicidal ideation within 30 days prior to providing written informed consent (evidenced by answering yes to either question 1 or 2 on the C-SSRS) or a history of a suicide attempt in the 6 months prior to consent
  • Has any active medical condition (including organ disease), psychiatric illness, social/legal situation (including court order requiring treatment for OUD), or concurrent medication/treatment that may compromise participant safety, interfere with study endpoints, limit compliance with study requirements, or compromise the ability of the participant to provide written informed consent
  • Has active hepatitis B or C as evidenced by positive serology and PCR test confirmation
  • Has total bilirubin ≥1.5 × ULN (with direct bilirubin >20% of total bilirubin), ALT ≥3 × ULN, AST ≥3 × ULN, or INR >1.5 × ULN at Screening)
  • Has serum creatinine >1.5 × ULN or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 by CKD-EPI formula
  • Has known allergy or hypersensitivity to BUP, any excipients of INDV-6001, SUBOXONE, or SUBLOCADE
  • Is currently participating in another interventional clinical study, and/or has been treated with investigational product INDV-2000 within 1 month prior to Screening Visit, or another investigational agent within 3 months prior to Screening Visit
  • Is currently being treated with medications contraindicated for use with BUP as per local prescribing information
  • Has donated more than 500 mL of blood within the past 3 months prior to consent
  • Is a member of site staff, has a financial interest in Indivior, or is an immediate family member of anyone directly involved in the study (eg, site staff or Indivior employee)

Where in United States

  • Progressive Clinical ResearchBountiful, United States
  • Chicago Clinical Research Institute INCChicago, United States
  • Midwest Clinical ResearchDayton, United States
  • InSite Clinical Research, LLCDeSoto, United States
  • Precise Research CentersFlowood, United States
  • Memorial Hermann VillageHouston, United States
  • Hassman Research Institute (Cenexel HRI - Marlton)Marlton, United States
  • Innovative Clinical Research, Inc.Miami Lakes, United States
  • Pillar Clinical ResearchRichardson, United States
  • Artemis Institute for Clinical ResearchSan Diego, United States
  • Richmond Behavioral AssociatesStaten Island, United States

About the trial

What the trial wants to find out

This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5).

Read full original descriptionShow less

The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE®) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE®). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.

The 9 groups in the trial

  • Cohort 1Treatment being tested

    SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 600 mg on Day 8, Day 92, and Day 176)

    Treatment: INDV-6001 and Suboxone

  • Cohort 2Treatment being tested

    SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 600 mg on Day 8, Day 64, Day 120, and Day 176)

    Treatment: INDV-6001 and Suboxone

  • Cohort 3Treatment being tested

    SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, 600 mg Day 8, followed by 250 mg on Day 15, Day 43, Day 71, and Day 99)

    Treatment: INDV-6001 and Suboxone

  • Cohort 4Treatment being tested

    SUBOXONE 12-16 mg once daily (to continue through Day 7), followed by INDV-6001 (600 mg Day 1, followed by 100 mg on Day 8, Day 36, Day 64, and Day 92)

    Treatment: INDV-6001 and Suboxone

  • Cohort 1aTreatment being tested

    In Cohort 1, up to 15 participants who reach Day 260 will be enrolled into Cohort 1a. Participants in Cohort 1a will receive an additional injection of INDV-6001 600 mg in the back of the upper arm on Day 260.

    Treatment: INDV-6001

  • Cohort 2aTreatment being tested

    In Cohort 2, up to 15 participants who reach Day 232 will be enrolled into Cohort 2a. Participants in Cohort 2a will receive an additional injection of INDV-6001 600 mg in the thigh on Day 232.

    Treatment: INDV-6001

  • Cohort 3aTreatment being tested

    In Cohort 3, up to 15 participants who reach Day 127 will be enrolled into Cohort 3a. Participants in Cohort 3a will receive an injection of SUBLOCADE 300 mg (abdomen) on Day 127.

    Treatment: Sublocade

  • Cohort 4aTreatment being tested

    In Cohort 4, up to 15 participants who reach Day 120 will be enrolled in Cohort 4a. Participants in Cohort 4a will receive an injection of SUBLOCADE 100 mg (abdomen) on Day 120.

    Treatment: Sublocade

  • Cohort 7Treatment being tested

    Participants in Cohort 7 who are new to BUP treatment will undergo rapid induction with SUBLOCADE 300 mg (per product labelling) in the abdomen on Day 1 following an initial dose of SUBOXONE (eg, 4 mg). All participants in Cohort 7 will receive: SUBLOCADE 300 mg (abdomen) on Day 1 and Day 8, SUBLOCADE 100 mg (abdomen) on Day 36, and 600mg INDV-6001 on Day 64.

    Treatment: INDV-6001, Suboxone, and Sublocade

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Multicentre Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Repeated Doses of INDV-6001 in Adults With Moderate to Severe Opioid Use Disorder
Record updated
16 March 2026